POLYMORPHISMS OF HPC2/ELAC2 AND SRD5A2
(5α-Reductase Type II) GENES IN PROSTATE CANCER İzmirli M1,*, Arikan B2, Bayazit Y3, Alptekin D4 *Corresponding Author: Muzeyyen İzmirli, Department of Medical Biology, Faculty of Medicine, Bezmialem
Vakif University, 34093, Istanbul, Turkey; Tel.: +90-212-523-37-19, Fax: +90-212-523-23-26;
E-mail: muzeyyenizmirli@gmail.com. page: 31
|
DISCUSSION
We found significant differences between the patient
and control groups for Ser217Leu in the HPC2/ELAC2 gene and for Ala49Thr in the SRD5A2 gene.
However, we did not see any difference between the
patient and control groups for Ala541Thr in the HPC2/
ELAC2 gene and for Val89Leu in the SRD5A2 gene.
There is controversy on the role of HPC2/ELAC2
and SRD5A2 genes in prostate cancer. They focus on
different populations or populations from different regions
in the same country.
There are several studies which reveal that there is
correlation between prostate cancer patients and their
ethnic backgrounds. Some of the investigated populations
were Caucasian, African-American, Asian, Canadian, American-Caucasians and British for the
Ser217Leu polymorphism in the HPC2/ELAC2 gene
[4,12,15]. Our findings in the Turkish population for the
correlation between the Ser217Leu polymorphism in
the HPC2/ELAC2 gene and prostate cancer risk agree
with those of the above-mentioned studies. In contrast
with those findings, no association was found between
Ser217Leu polymorphism in the HPC2/ELAC2 gene
in Finnish, Caucasian, African-American and American-
Caucasian prostate cancer patients [16-18].
The other polymorphism is Ala541Thr for the
HPC2/ ELAC2 gene which has been studied by a number
of investigators for different populations. Some of
these results for Canadian, Japanese, African-American
and American-Caucasian and Asian populations
were statistically significant [4,13,15,19]. However,
some results of Caucasian, Finnish and British men
with prostate cancer were not statistically significant
which are in agreement with our findings [14,16,17].
There are a number of studies based on the investigation
of different populations with the Ala49Thr polymorphism
in the SRD5A2 gene. Some studies for African-
American, Hispanic, Caucasians, French and American
men [9,11,20,21] had similar results which indicates a
significant difference between the Ala49Thr polymorphism
in the SRD5A2 gene and prostate cancer patients.
However, negative findings were reported by several
studies about Chinese and Turkish populations [20,21].
In contrast, we showed significant differences between
patients and controls regarding the Thr49 allele.
In a previously published study, the Val89Leu
polymorphism was investigated for Japanese, Indian,
French, Caucasian, Chinese and Turkish populations.
It has recently been shown that there was no correlation
between the Val89Leu genotype and prostate cancer
[9,21-23,26, 27]. Our results also support the findings
of these studies based on the SRD5A2 gene in Turkish
men with prostate cancer. According to statistical data,
some of the screened populations were significantly
different. They were Canadian, American and Caucasian
populations [11,24,25]. However, Soderstrom et
al. [28] published that the Leu89 allele decreased the
risk of prostate cancer about 6.67-fold.
In conclusion, genetic polymorphisms are affected
by ethnic backgrounds. In order to reveal the correlation
between some polymorphisms and prostate cancer,
we investigated the Ser21Leu and Ala541Thr polymorphisms
in the HPC2/ ELAC2 gene and Ala49Thr and
Val89Leu polymorphisms in the SRD5A2 gene in a Turkish population with prostate cancer. We found correlations
between the Ser217Leu and Ala49Thr polymorphisms
and the disease according to our sample
size. In order to get a certain result about the relation,
larger samples are needed; depending on this, further
studies may achieve the exact correlation.
|
|
|
|
|
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|